Suppr超能文献

相似文献

1
Shared Mechanisms between Cardiovascular Disease and NAFLD.
Semin Liver Dis. 2022 Nov;42(4):455-464. doi: 10.1055/a-1930-6658. Epub 2022 Aug 25.
2
Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Causation or Association.
Cardiol Rev. 2024;32(5):453-462. doi: 10.1097/CRD.0000000000000537. Epub 2023 Feb 24.
3
Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review.
Diabetes Obes Metab. 2021 May;23(5):1069-1083. doi: 10.1111/dom.14322. Epub 2021 Feb 10.
4
Nutritional supplementation for nonalcohol-related fatty liver disease: a network meta-analysis.
Cochrane Database Syst Rev. 2021 Jul 19;7(7):CD013157. doi: 10.1002/14651858.CD013157.pub2.
5
Comparative association between NAFLD and MAFLD with cardiovascular events and mortality: Evidence from observational studies.
PLoS One. 2025 Jun 13;20(6):e0312650. doi: 10.1371/journal.pone.0312650. eCollection 2025.
6
Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review.
Health Technol Assess. 2011 Nov;15(38):1-110. doi: 10.3310/hta15380.
7
Lifestyle modifications for nonalcohol-related fatty liver disease: a network meta-analysis.
Cochrane Database Syst Rev. 2021 Jun 11;6(6):CD013156. doi: 10.1002/14651858.CD013156.pub2.
8
Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: A systematic review and meta-analysis.
Metabolism. 2018 Feb;79:64-76. doi: 10.1016/j.metabol.2017.11.003. Epub 2017 Nov 11.
9
A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care?
Atherosclerosis. 2013 Oct;230(2):258-67. doi: 10.1016/j.atherosclerosis.2013.07.052. Epub 2013 Aug 9.
10
Nonalcoholic fatty liver disease and hepatocellular carcinoma.
Metabolism. 2016 Aug;65(8):1151-60. doi: 10.1016/j.metabol.2016.01.010. Epub 2016 Jan 23.

引用本文的文献

1
Atherogenic Combined Index is Independently Associated with MASLD in Type 2 Diabetes: A Cross-Sectional Study.
Diabetes Metab Syndr Obes. 2025 Aug 25;18:3041-3052. doi: 10.2147/DMSO.S523139. eCollection 2025.
2
Regulating Effect of Weekend Catch-up Sleep on Association of Hepatic Steatosis with Atherosclerotic Cardiovascular Disease.
Balkan Med J. 2025 May 5;42(3):233-241. doi: 10.4274/balkanmedj.galenos.2025.2025-1-87.
3
Metabolic dysfunction-associated steatotic liver disease in adults.
Nat Rev Dis Primers. 2025 Mar 6;11(1):14. doi: 10.1038/s41572-025-00599-1.
4
Association of Steatotic Liver Disease with Retinal Vascular Occlusion: The Influence of Obesity in a Large Health Screening Cohort.
Endocrinol Metab (Seoul). 2025 Apr;40(2):299-303. doi: 10.3803/EnM.2024.2181. Epub 2025 Feb 12.
5
Higher risk of carotid plaque among lean individuals with non-alcoholic fatty liver disease: A retrospective study.
PLoS One. 2025 Feb 3;20(2):e0316997. doi: 10.1371/journal.pone.0316997. eCollection 2025.
7
[Serum indices of hepatic steatosis in indigenous Venezuelan adults of the Piaroa ethnic group].
Rev Fac Cien Med Univ Nac Cordoba. 2024 Dec 13;81(4):686-704. doi: 10.31053/1853.0605.v81.n4.44477.
9
Association Between Noninvasive Liver Fibrosis Scores and Heart Failure in a General Population.
J Am Heart Assoc. 2024 Nov 19;13(22):e035371. doi: 10.1161/JAHA.123.035371. Epub 2024 Nov 7.

本文引用的文献

1
Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer.
Cell Metab. 2022 Jul 5;34(7):969-977.e2. doi: 10.1016/j.cmet.2022.05.003. Epub 2022 Jun 3.
2
Non-alcoholic fatty liver disease association with structural heart, systolic and diastolic dysfunction: a meta-analysis.
Hepatol Int. 2022 Apr;16(2):269-281. doi: 10.1007/s12072-022-10319-6. Epub 2022 Mar 23.
6
2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis.
Clin Gastroenterol Hepatol. 2022 Dec;20(12):2809-2817.e28. doi: 10.1016/j.cgh.2021.12.002. Epub 2021 Dec 7.
7
Nonalcoholic fatty liver disease and risk of incident hypertension: a systematic review and meta-analysis.
Eur J Gastroenterol Hepatol. 2022 Apr 1;34(4):365-371. doi: 10.1097/MEG.0000000000002299.
8
A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH.
N Engl J Med. 2021 Oct 21;385(17):1547-1558. doi: 10.1056/NEJMoa2036205.
9
A Meta-Analysis on the Global Prevalence, Risk factors and Screening of Coronary Heart Disease in Nonalcoholic Fatty Liver Disease.
Clin Gastroenterol Hepatol. 2022 Nov;20(11):2462-2473.e10. doi: 10.1016/j.cgh.2021.09.021. Epub 2021 Sep 22.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验